MedTrace Logo

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

NCT05548777 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5480

Last updated 2023-11-28

No results posted yet for this study

Summary

This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed, and their characteristics, treatments and outcomes will be described.

Conditions

  • Anticoagulant-related Major Bleed

Interventions

DRUG

Andexanet alfa

Andexanet alfa

DRUG

4F-PCC

Four-Factor Prothrombin Complex Concentrate (4F-PCC)

Sponsors & Collaborators

  • Outcomes Insights

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548777 on ClinicalTrials.gov